The weekly litigation news digest is live. Subscribe now

IP Verse

Compositions Comprising Sphingosine I Phosphate (Sip) Receptor Modulators - EP2952177

The patent EP2952177 was granted to Novartis on Jan 20, 2021. The application was filed on Oct 9, 2008 under application number EP15173766A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2952177

NOVARTIS
Application Number
EP15173766A
Filing Date
Oct 9, 2008
Status
Granted And Under Opposition
Dec 18, 2020
Publication Date
Jan 20, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
TEVA PHARMACEUTICALSMay 4, 2023D YOUNGINTERVENTION WITHDRAWN
TEVA PHARMACEUTICALSSep 22, 2022D YOUNGINTERVENTION WITHDRAWN
ACCORD HEALTHCAREOct 20, 2021HOFFMANN EITLEWITHDRAWN

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONWO2005025553
OPPOSITIONEP0812588
OPPOSITIONEP1201236
OPPOSITIONWO2004089341
OPPOSITIONWO2005002559
OPPOSITIONWO2005025553
OPPOSITIONWO2006102611
SEARCHWO2004089341
SEARCHWO2007021666
SEARCHWO2008037421

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents